Tokyo, July 8 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058380) titled 'Prevalence of sarcopenia and respiratory sarcopenia after chimeric antigen receptor gene-modified T cell therapy' on July 7.
Study Type:
Observational
Primary Sponsor:
Institute - Hyogo Medical University
Condition:
Condition - Malignant lymphoma, multiple myeloma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To investigate the prevalence of sarcopenia and respiratory sarcopenia after CAR-T cell therapy.
Basic objectives2 - Safety
Eligibility:
Age-lower limit - 18
years-old
=
Gender - Male and Female
Key inclusion criteria - Patients scheduled to undergo CAR...